Key Sessions
David Ferland-McCollough
Chair Remarks: Spotlight on Montreal
AReNA
Karina Thorn
Panel: RNA Drug Discovery - Fostering the Next Wave of RNA Medicines
Novo Nordisk
Friday, September 25 - EST (Eastern Time, UTC-05:00
Friday, September 25 - EST (Eastern Time, UTC-05:00
8:30am - 8:55am25 mins
Registration
8:55am - 9:00am5 mins
Oligo-based Therapeutics: ASOs Clinical Advancements
Chair Remarrks
8:55am - 9:00am5 mins
mRNA & Next-Gen RNA: Non-Linear Innovation
Chair Remarrks
9:00am - 9:25am25 mins
Oligo-based Therapeutics: ASOs Clinical Advancements
An Investigational ASO for Dravet Syndrome
- Isabel Aznarez, Ph.D - Co-founder & Chief Technology Officer, Stoke Therapeutics
9:00am - 9:25am25 mins
mRNA & Next-Gen RNA: Non-Linear Innovation
Advancing circRNA expression systems applied to in vivo CAR cell Therapy
- Lubor Gaal - CFO, Circio AB
9:25am - 9:50am25 mins
Oligo-based Therapeutics: ASOs Clinical Advancements
Phase 1a Clinical Trial of TTX-MC138, a First-in-Class Antagomir against Advanced Solid Tumors
- Zdravka Medarova, PhD - Co-Founder and Chief Scientific Officer, TransCode Therapeutics
9:25am - 9:50am25 mins
mRNA & Next-Gen RNA: Non-Linear Innovation
In Vivo CAR T with RNA Medicines for Scalable and Safe Immune Cell Reprogramming
- Michael Lam, Ph.D - VP, Head of Corporate and Scientific Strategy, Sail Biomedicines
9:50am - 10:15am25 mins
Oligo-based Therapeutics: ASOs Clinical Advancements
Development and progression to the clinic of antisense oligonucleotide to advance treatment of ALS and FTD
9:50am - 10:15am25 mins
mRNA & Next-Gen RNA: Non-Linear Innovation
Harnessing circRNA therapeutics for durable and tolerable treatments in oncology and autoimmune diseases - Preclinical Updates
- Peter Weinstein - CEO, Circurna
10:15am - 10:40am25 mins
Oligo-based Therapeutics: ASOs Clinical Advancements
Innovating Oligonucleotide Production: Chemoenzymatic Synthesis
- Wuming Yan - Chief Scientist Oligonucleotides, Asymchem
10:15am - 10:40am25 mins
mRNA & Next-Gen RNA: Non-Linear Innovation
Technology Presentation Opportunity Available
10:40am - 11:20am40 mins
Morning Networking Break
11:20am - 11:45am25 mins
Oligo-based Therapeutics: siRNA Clinical Advancements
Clinical Progression of siRNA ARO-MAPT Phase 1/2a Study for Alzheimer’s Disease
- Roger Chang - Associate Medical Director, Arrowhead
11:20am - 11:45am25 mins
mRNA & Next-Gen RNA: Clinical Advancements
Advancing tRNA Therapeutics for Stop Codon Disease: Preclinical Data Supporting a Basket Clinical Development Strategy
- Dave Hava - CSO, Alltrna
11:45am - 12:10pm25 mins
Oligo-based Therapeutics: siRNA Clinical Advancements
From Concept to Clinic: Best-in-Class RNAi Therapeutics for Obesity, Cardiometabolic, and Autoimmune Diseases Powered by LEAD™
- Weimin Wang, PhD - Founder & CEO, Sanegene Bio
11:45am - 12:10pm25 mins
mRNA & Next-Gen RNA: Clinical Advancements
Advancing mRNA Therapeutics with Strand Signal Stack
- Tasuku Kitada - President and Head of R&D, Strand Therapeutics
12:10pm - 12:35pm25 mins
Oligo-based Therapeutics: siRNA Clinical Advancements
Advancing PGN-EDODM1, an enhanced peptide for clinical studies to treat DMD1
12:10pm - 12:35pm25 mins
mRNA & Next-Gen RNA: Clinical Advancements
Advancing Therapeutic Angiogenesis: First-in-Human Trial of HM2002 Circular RNA Therapy for Ischemic Heart Failure in CABG Patients
12:35pm - 1:00pm25 mins
Oligo-based Therapeutics: siRNA Clinical Advancements
Advancing siRNA Manufacture From Conventional to Thermostable Enzymatic Ligation
- Xiaocen (Chris) Li, PhD - Director of Oligonucleotide Science and Technology, Hongene
12:35pm - 1:00pm25 mins
mRNA & Next-Gen RNA: Clinical Advancements
Technology Presentation Opportunity Available
1:00pm - 2:20pm80 mins
Lunch or sign up for the Women in RNA Networking Lunch & Sparkling Reception
2:20pm - 2:35pm15 mins
Keynote Session
Chair Remarks: Spotlight on Montreal
- David Ferland-McCollough - Innovation Advisor, AReNA
2:35pm - 3:25pm50 mins
Keynote Session
Panel: RNA Drug Discovery - Fostering the Next Wave of RNA Medicines
- Karina Thorn - Vice President, Head of Nucleic Acid Research, Novo Nordisk
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
- Malgorzata Gonciarz - Global Head xRNA Therapeutics, Novartis
- Shraddha Sharma - Director, Discovery Biology, Sanofi
3:25pm - 3:30pm5 mins
Keynote Session
Closing Remarks
- Jade Osei-Tutu - Head of RNA Leaders, Informa Connect
3:30pm - 3:35pm5 mins
Close of Congress
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.